Albany, NY -- (SBWIRE) -- 04/08/2013 -- TechNavio's analysts forecast the Global Plasma market to grow at a CAGR of 10.31 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in the aging population. The Global Plasma market has also been witnessing the trend of increasing market consolidation. However, stringent regulations could pose a challenge to the growth of this market.

To Buy the Copy Of This Report Visit: http://www.marketresearchreports.biz/analysis-details/global-plasma-market-2012-2016

TechNavio's report, the Global Plasma Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global plasma market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this space CSL Behring LLC, Baxter International Inc., Grifols S.A., and Octapharma AG

Other vendors mentioned in the report are Kedrion S.p.A., Biotest AG, Sanguine Corp., Cangene bioPharma Inc., Haemacure Corp., Kamada Inc., Omrix Biopharmaceuticals Inc., Vivostat A/S, Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Inc., Novo Nordisk A/S, sanofi S.A., China Biologic Products Inc., Beijing Tiantan Biological Products Co. Ltd., Bharat Serums and Vaccines Ltd., and LFB Group.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis/165328

Key questions answered in this report:
What will the market size be in 2016 and at what will be the growth rate?
What are key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by key vendors?
What are the strengths and weaknesses of each of these key vendors?

Related Reports:

Plasma Cell Neoplasm Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, Plasma Cell Carcinoma Global Clinical Trials Review, H1, 2012" provides data on the Plasma Cell Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Plasma Cell Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Plasma Cell Carcinoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Plasma Cell Neoplasm Pipeline Review, H2 2012

Global Markets Directs, 'Plasma Cell Neoplasm Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Plasma Cell Neoplasm, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Plasma Cell Neoplasm. Plasma Cell Neoplasm Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

For All Market Research Reports visit: http://www.marketresearchreports.biz/